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Summary 
Superantigens are thought to make external  contacts with major histocompatibility complex 
(MHC) class II molecules and with the VB portion of a T cell antigen receptor (TCR), thereby 
stimulating entire families of T cells. The precise mapping of superantigen binding sites on class 
II molecules may provide valuable information on how TCR and MHC molecules interact. Two 
bacterial superantigens, staphylococcal enterotoxins A and E (SEA/SEE) bind well to most HLA-DR 
alleles, but poorly to HLA-DRw53. The sequences responsible for this binding were localized 
to the putative oe helix of the DR 3  chain by measuring toxin binding to a panel of chimeric 
class II molecules expressed on transfected  cells. Binding of SEA/SEE  to the DRw14 (Dw9) 
molecule suggested that the conserved histidine 81 in the ~ chain of most DR molecules was 
important, whereas the tyrosine 81 in the DRw53/J chain was detrimental for high-affinity 
binding. To prove this, reciprocal point mutations were introduced in the DR1 and DRw53 
chains. Mutation of histidine 81 in the DR1 3  chain to tyrosine reduced SEA/SEE binding, 
but did not prevent recognition of two DRl-restricted peptides by six of eight antigen-specific 
T cell lines. Conversely, introduction of histidine at position 81 in the DRw53 3 chain restored 
normal levels of SEA/SEE binding. These data suggest that a binding site of SEA and SEE lies 
on the outer face of the B chain oe helix, pointing away from the antigen-binding groove. 
T 
he class II molecules of the MHC include the HLA- 
DR, -DQ, and -DP antigens in humans, and the IA and 
IE antigens in the mouse. They are polymorphic cell surface 
heterodimers  consisting  of  a  noncovalently-associated 
"o35,000-dalton  oe chain and a "o29,000-dalton/3 chain (1, 
2). Class II molecules function by binding small (9-12 amino 
acid) peptides derived from the processing of exogenous mac- 
romolecular antigens and subsequently presenting them to 
CD4 + T  lymphoeytes. Little is known about the physical 
interaction of class II molecules with their principal ligands, 
the TCR variable regions and the T  cell coreceptor CD4. 
Models have been proposed predicting the way that MHC 
molecules may interact with CD4 and TCR (3, 4), but due 
to the low avidity of these interactions, no direct binding 
data have been reported. 
Certain bacterial toxins are also ligands for class II. These 
include the Staphylococcus  aureus  enterotoxins (SEA, 1 SEB, 
1Abbreviations  used  in  this paper:  Mls,  minor lymphocyte  system; SE, 
staphylococcal enterotoxin;  TSST, toxic shock syndrome toxin. 
A preliminary account of this work was presented at the Federation of 
American Societies for Experimental  Biology, Atlanta,  GA, April 21- 
25,  1991. 
SECI,2,3, SED, and SEE) and the toxic shock syndrome toxin 
(TSST-1). The staphylococcal toxins are potent polyclonal ac- 
tivators of T cells (5, 6). There is no requirement for pro- 
cessing of the toxins similar to typical antigens.  Proteolysis 
of the toxins abrogates  their activity (7). The activation of 
T cells results in proliferation, cytolytic activity,  and secre- 
tion of IL-2 and IFN-3,.  T cell populations activated by the 
staphylococcal toxins are polyclonal, yet each superantigen 
appears  to  preferentially  stimulate  T  cells bearing  TCR 
representing one (or a few) particular V3 family (8, 9). Di- 
rect binding of many of the toxins to class II has been demon- 
strated:  SEA and SEB to HLA-DR (7); SEA to HLA-DR, 
-DQ, and -DP (10); and TSST-1 to HLA-DR and -DQ, but 
not to HLA-DP (11). The Kd's for the interaction of the var- 
ious toxins with class II molecules determined were in the 
range of 10-6 to 10 -s M. 
The term superantigen has been used to describe substances 
with the ability to activate large numbers of T cells in a class 
II-dependent but unrestricted fashion (8). The staphylococcal 
toxins are the best studied super'antigens,  but there is a growing 
number of microbial products that fit this category. These 
include the Mycoplasma arthriditis mitogen (12) and the strep- 
tococcal M protein (13). Other superantigens have been par- 
tially characterized  from group A streptococcus and Gram- 
negative bacteria. The Mls (minor lymphocyte system) in mice 
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ticular Mls determinants are associated with specific endoge- 
nous murine retroviruses  (14-16).  In one case,  the Mls re- 
sponse was duplicated by transfection of lymphocytes with 
DNA derived from an open reading frame in the 3' retroviral 
LTK (17). Other retroviral proteins have been suggested to 
act  as superantigens  (18). 
The molecular mechanism by which the toxins interact 
with class II is poorly understood. The toxins appear to bind 
outside the antigen-binding groove of class II. Preincubation 
of HLA-DK-expressing cells with  a saturating  amount  of 
TSST-1 neither prevented nor diminished  the binding  of a 
known  antigenic  peptide  (19).  Furthermore,  an  alanine- 
scanning mutagenesis of the oe-helical portion of the IA  k ol 
chain failed to identify a residue that was essential for SEB, 
SEC1,  or exfoliative toxin  action,  whereas many mutants 
affected the recognition of specific antigenic peptides by T 
cells (20). The conclusion that the toxins make external con- 
tacts with class II molecules is consistent with the observa- 
tion that residues of the Vfl region of the TCK that are im- 
portant for toxin action are postulated to lie on an exposed 
face of the receptor (21).  The precise mapping  of superan- 
tigen binding sites on class II molecules would provide valu- 
able information  about how MHC and TCK interact. 
Several clues to the nature of the toxin binding site(s) have 
been derived from the hierarchy of interaction that exists for 
many of the isotypes and alleles of class II. The oll domain 
of HLA-DK1 was shown to be essential for the high-affinity 
binding of TSST by producing a series of homologue scan- 
ning mutants with sequences derived from the DR or the 
DP molecules (19).  The importance of the DR o~ chain in 
TSST binding was confirmed by testing mouse/human  hy- 
brid class II molecules (22). The mouse IE molecule, although 
homologous to DR, does not bind TSST.  Cells expressing 
class II consisting of the DR o~ chain in combination with 
the IE 3 chain bound TSST, and cells expressing an IE oe/DR,8 
heterodimer  did not.  Several toxin binding  sites  may exist 
on class II molecules. TSST and SEB bind independent  of 
each other to HLA-DK1 or HLA-DQwl (23). In addition, 
SEA is an effective competitor of SEB binding to HLA-DR, 
and SEB did not inhibit the binding of SEA, even at a 1,000- 
fold excess (7). SEA can also inhibit TSST binding, and, again, 
the converse is not true (D. Karp, unpublished results). This 
suggests the possibility of several, possibly overlapping, binding 
sites  for the staphylococcal toxins on class  II. 
The HLA-DRw53 molecule was found to be ineffective 
in the binding of SEA and SEE when compared with HLA- 
DR1 (24). This molecule is composed of the nonpolymorphic 
DR o~ chain and the DRw53 ~  chain (DRB4*0101  allele). 
This suggested a binding site for SEA and SEE in the B chain, 
a conclusion supported by peptide inhibition experiments (25). 
The present investigation uses molecular techniques to iden- 
tify residues critical for binding  of SEA and SEE.  Mutant 
human  class II molecules containing  sequences from DR1 
and DRw53 localize the binding of intact toxins to the puta- 
tive ol-helical  region of the 81 domain.  Site-directed muta- 
genesis has identified position 81 of the B chain as a critical 
residue in the interaction  with  these two toxins. 
Materials and Methods 
L  Cells Expressing HLA-DR Mutants.  Expressible  cDNA for 
the/3 chain of DR1 was cloned into the vector KSV.3 as described 
(26). This construct  has unique Sad and HindlII restriction  en- 
donuclease sites in the DR leader sequence and 3' untranslated re- 
gion,  respectively. These sites are conserved in cDNA for many 
DIL8 alleles including DKw53 and DKw14(Dw9). The plasmid, 
KSV.3 DK1/3, was digested with Sad and HindIII, and the DK1 
/3 chain coding sequence  rephced by cDNA from DKw53 (provided 
by Dr. Kobert Karr, Monsanto Corp., St. Louis, MO) and DKw14 
/3 chains (provided by Dr. Jack Gorski, Blood Research Institute, 
Milwaukee, WI), digested with the same enzymes. 
The cDNA for DR1 and DRw53/3 chains were also cloned 
into the vector pBluescript SK (Stratagene Inc., La Jolla, CA) to 
create pSKDR1/3 and pSKDKw53/3, respectively. A unique ScaI 
site occurs at codon 59 of the/3 chain  sequence. Digestion  of 
pSKDK1/3 and pSKDKw53/3 with ScaI and ClaI produced three 
fragments: a ClaI-ScaI fragment containing NH2-termina] cDNA 
sequences, a ScaI-ScaI fragment including COOH-terminal cDNA 
sequences and a portion of the vector, and a ScaI-ClaI fragment 
having the remainder of the vector. These fragments were sepa- 
rated by gel electrophoresis and appropriate fragments were iso- 
lated and religated. This created two chimeric cDNA molecules. 
DR. 153.59 had codons 1-59 derived from DR1 and the remainder 
from DRw53, DR 531.59 had codons  1-59 from DR`w53, and 
the remainder from DR1. 
To create the pair of mutants having/31 domains (codons 1-94) 
derived from either DR`I or DR`w53, and/32 domains  (codons 
95-237) derived from the other allele, the technique of synthesis 
by overlap extension was used (27). Oligonucleotides were synthe- 
sized corresponding to conserved regions of the DR`/3 chain cDNA 
sequence in the leader region  (codons 1-6, sense direction),  the 
cytoplasmic tail (codons 224-230,  antisense direction),  and the 
COOH-terminal portion of the/31  domain (codons 88-94, both 
directions). These oligonucleotides were used to amplify 81 and 
/32 domain sequences from DR`I and DR`w53/3 chain cDNA using 
PCR`. Amplified products were isolated by agarose gel electropho- 
resis, and purified with GeneClean (Biol01, Inc., Vista, CA). DNA 
corresponding to the/31 domain of  DR`l was combined with DNA 
for the/32 domain of DRw53, and oligonucleotide primers from 
the leader and cytoplasmic regions. After a second amplification 
by PCR, the full-length products were isolated by gel electropho- 
resis, purified, and digested with Sad and StuI. These fragments 
were ligated to fragments of RSV.3 DR1/3 and ILSV.3 DR`w53/3 
digested with these same enzymes. This created DR` 153.94 (having 
the/31 domain of DR1 and/32 domain of DKw53) and DR` 531.94 
(having the/31  domain of DKw53 and/32 domain of DR`l). 
Point mutations  in the/3 chain cDNA were made in a similar 
manner. Oligonucleotide  primers corresponding to codons 78-84 
(both directions) of the DR`I and DR`w53 B chains were synthe- 
sized such that codon 81 of the DR`I sequence would be a tyrosine 
and codon 81 of the DR`w53 sequence would be histidine. These 
primers were used with the primers from the leader and cytoplasmic 
sequences described above to create full-length cDNA having the 
single amino acid change. Fragments of these cDNA were used 
to replace sequences from R`SV.3 DR`l/3 or R`SV.DR`w53/3, as ap- 
propriate. The authenticity  of the point mutations,  as well as the 
chimeric cDNA sequences, was verified  by determining the sequence 
of the the entire/3 chain coding region of each clone before use 
in transfection experiments. 
The plasmid, R`SV.5(neo) DR`or (28) has an expressible cDNA 
for the nonpolymorphic DR` c~ chain under the control of the RSV 
LTR`, as well as the bacterial neomycin resistance gene under the 
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fected with an expressible wild-type or mutant fl chain eDNA into 
L cells as described (28). Transfected cells were selected and main- 
tained in DME plus 10% FCS containing G418 (0.5 mg/ml, active 
drug, Gibco-Bethesda Research Laboratories,  Gaithersburg, MD). 
Surviving cells from each transfection were pooled and stained with 
the anti-DR mAb, L243. A FACStar Plus  |  flow cytometer (Becton 
Dickinson and Co., Mountain View, CA) equipped with an Auto- 
matic Cell Deposition Unit was used to clone transfected cells on 
the basis of surface expression of DR molecules. 
Toxin Binding Assay.  SEA, SEK SEE, and TSST were were all 
purchased lyophilized from Toxin Technologies (Madison,  WI). 
They were dissolved in sterile water at a concentration of 1 mg/ml 
and diluted to 10 #g/ml in PBS containing 1% BSA and 0.1% 
gelatin just before use. 5  x  10  s L cells were incubated at 4~  with 
the various toxins for 2 h. The cells were washed, then incubated 
with toxin-specific  polyclonal rabbit antiserum (Toxin Technolo- 
gies), diluted 1:100 in PBS/BSA/gelatin, and incubated on ice for 
I h. Cells were washed again and incubated for 30 min on ice with 
FITC-labeled goat anti-rabbit IgG. Bound toxin, was determined 
by microcytofluorimetry. Controls for each cell type were incubated 
with antitoxin and fluoresceinated antibody without prior toxin 
binding.  Each cell  type was  simultaneously analyzed for L243 
binding. Data for toxin binding are corrected for different levels 
of class II expressed by different transfectants  as follows: (PCFto~n/ 
PCR~ontrol) -  1]/(PCFL243/PCFG^Mm).  Where PCF,o~ is the peak 
fluorescence value in the presence of toxin, PCFcon,rol  is the value 
in the absence  of toxin, PCFL243 is the peak fluorescence of the 
anti-DR reagent, PCFc~a~G is the fluorescence of the second an- 
tibody alone. The toxin/control ratio is reduced by 1 to reveal the 
fractional increase in fluorescence  due to toxin binding. 
T Cell Lines.  Fresh PBL were obtained from a normal HLA- 
DR1 volunteer. 13  x  106 cells were seeded in 10 ml of IMDM 
supplemented with 2 mM t-glutamine, 10% human serum, and 
5/zg/ml of either influenza matrix peptide M1(18-29) or hemag- 
glutinin peptide H3(307-318). After 10 d, 103 live cells were trans- 
ferred into wells of a 24-well plate containing 2 ml of IMDM sup- 
plemented with glutamine,  10%  human serum,  and  106 feeder 
cells. Feeder cells were prepared by incubating autologous PBL in 
IMDM supplemented with glutamine and 10/~g/ml of either pep- 
tide for 3 h, irradiated (2,000 tad), and washed.  After 6 d, 106 live 
cells were restimulated in a volume of 5 ml with 3-4  x  10  ~ ir- 
radiated feeder cells prepared as above. After five additional days, 
responder T cells were assayed for their ability to lyse target B cells 
incubated with peptide. Both the M1- and H3-stimulated popula- 
tion of T cells displayed peptide-specific  target cell lysis. 2 d later, 
T cells were seeded at 10 cells/well in three round-bottomed 96- 
well plates. Each well contained 0.2 ml IMDM supplemented with 
glutamine, human serum, and 25 U/ml rib2 (Cdlular Products, 
Buffalo,  NY),  and  103 irradiated and peptide-pulsed autologous 
feeder cells. The first addition of exogenous Ib2 occurred at this 
cloning step. After 12 d, growing T cells were tested for their ability 
to kill target cells in a peptide-specific manner. Lines that displayed 
specificity were expanded by repeated stimulations at 5-6-d intervals 
with irradiated peptide-pulsed feeder cells, and addition of 5 U/ml 
rlL-2 1 d after restimulation. Based on their cloning efficiency, these 
lines  are either clonal or oligoclonal. 
Cytotoxicity Assays.  Cytolytic activity was measured by stan- 
dard chromium release assays. The HLA-hemizygous B cell line, 
45.1 (29), was used as a human DRl-positive target. About 0.5-1 
x  10  ~ cells were incubated with  10/~g/ml of either matrix or 
hemagglutinin peptide in 0.5 ml of RPMI 1640 supplemented with 
ghtamine, 40/~g/ml gentamycin, and 5% bovine serum (Hyclone 
Laboratories Inc., Logan, UT). After 1 h, 50 ~Ci Na[SlCr]O~ was 
added, and the cells incubated another 3  ￿  h. After two washes, 
5  ￿  103 live target cells were added to various numbers of effector 
cells  in  V-bottomed  96-well  plates.  For  staphylococcal  toxin- 
mediated cytotoxicity, 45.1 cells were incubated with either 0.1/zg/ 
ml SEA or 1/~g/ml SEE, as described above for peptide. When 
trypsinized L cells were used as target cells, they were incubated 
with 100 #g/ml of antigenic peptide and labeled as described above. 
2.5  x  103 L cells were added to V-bottomed wells, and incubated 
6 h with effector cells. E/T ratios of 10:1, 2.5:1, and 0.625:1 were 
used for B cell targets, and 20:1, 5:1, and 1.25:1 for L cells. Super- 
natants were harvested and counted. Percent specific lysis was cal- 
culated as 100 x  [(experimental  -  spontaneous release)/(maximum 
-  spontaneous release)]. Each point represents mean determina- 
tions from triplicate wells. Maximum and spontaneous release were 
determined by incubating targets in 1% Triton X-100 or medium, 
respectively. 
T CellProliferation  Assays.  Purified T cells were prepared from 
peripheral blood of normal volunteers as previously described (30). 
After rosetting with SRBC and treatment with t-leucine methyl 
ester, the cells were passed through nylon wool. Non-T cells were 
depleted by panning with mAb L243 (anti-HLA-DR), 63D3 (anti- 
CD14), and B73.1 (anti-CD16). L cell transfectants were treated 
with mitomycin C  (Sigma Chemical Co., St. Louis,  MO),  100 
/~g/ml,  at 37 ~ for 1 h and washed extensively.  T cells (6  x  104) 
and L cells (2  x  104) were co-cultured in round-bottomed 96-well 
plates with various dilutions of SEA or SEE in RPMI 1640 con- 
taining 10% heat-inactivated FCS.  After 50 h at 37~  the cells 
were pulsed with 1/zCi of [3H]thymidine (6.7 Ci/mmol), and cul- 
tured for an additional 16 h. Cells were harvested on glass fiber 
filters, and incorporated radioactivity was quantitated by liquid scin- 
tillation counting. 
Results 
Binding of SEA and SEE to DR1 Is Controlled by the ~1 
Domain.  Mouse L  cells were transfected with eDNA  for 
the nonpolymorphic DR a  chain and ~ chains from the DR1 
(DRB1 "0101) or DKw53 (DRB4*0101) alleles, or chimeric 
chains having sequences from both DR1 and DRw53. These 
cells were tested for their ability to bind the staphylococcal 
enterotoxins, SEA, SEB, SEE, and TSST (Fig. 1 A). As shown 
previously (24), there was a marked difference between DR1 
and DKw53 in the binding of SEA and SEE. For these two 
toxins, the level of binding to DKw53 (corrected for expres- 
sion of class II) was  1-5%  of that seen with DR1.  In con- 
trast,  there was no significant difference in the binding of 
either SEB or TSST to DR1  or DKw53.  The lower level 
of binding of these two toxins is consistent with their greater 
reported dissociation  constants  (31). 
Since  the  DR  o~  chain  is  common  to  both  DR1  and 
DRw53,  the sequences responsible for the high-affinity in- 
teraction with SEA and SEE must lie in the B chain. To iso- 
late the region of the B  chain containing these sequences, 
a series of homologue scanning mutants were constructed. 
The first pair of these mutants combined the membrane distal 
fll domain of one allele (amino acids 1-94) with the B2 do- 
main, transmembrane, and intracytoplasmic portions (amino 
acids 95-237) of the other. L cells expressing class II mole- 
cules comprised of these mutant ~ chains in association with 
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Figure 1.  Binding of staphylococcal toxins 
to wild-type and chimeric HLA-DR molecules. 
Mouse  L cells were  stably transfected with 
HLA-DR1, HLA-DRw53, or DR1/w53 chi- 
meras and tested for their ability to bind SEA, 
SEB, SEE, and TSST. In each panel, the y-axis 
is the relative binding  of the individual toxins 
as measured by microcytofluorimetry.  It is a 
dimensionless quantity as defined in Materials 
and Methods. (.4) Solid bar, HLA-DR1; hatched 
bar, HLA-DRw53. (/3) Solid bar, DR 153.94, 
a chimera having the ~1 domain of DR1 and 
the/~2 domain of DR.w53; hatched bar, DR 
531.94, a chimera having the/~1 domain of 
DKw53 and the B2 domain of DR1. (C) Solid 
bar, DR 153.59, a chimera having residues 1-59 
of DR.1 and the remainder of the B chain from 
DRw53; hatched bar, DR 531.59, a chimera 
with residues 1-59 from DRw53 and the rest 
of the/~ chain from DR1. (D) Solid bar, DR 
1.53.1,  a double chimera  with amino acids 
59-94 derived from DRw53 and the rest of 
the B chain from DR1; hatched bar, DR 53.1.53, 
a double chimera with the residues 59--94  from 
DK1 and the other residues  from DKw53. ND, 
None detected. 
the DR, cz chain  were tested for toxin binding (Fig.  1 B). 
Only the chimera  DR 153.94, which expresses the/31 do- 
main of DR1, was able to bind SEA and SEE. The reason 
for the increased binding of SEE to this mutant relative to 
the wild-type is unknown. The mutant DR, 531.94, expressing 
the 31 domain of DRw53, did not bind these two toxins, 
although  it did bind SEB and TSST. 
The next pair of mutants had the first 59 amino acids de- 
rived from one allele and the remainder  of the molecule de- 
rived from the other.  Residues  1-59 are predicted  to form 
the/3 sheet "floor" of the antigen-binding  groove (32). Thus, 
the mutant DR 153.59 had DRl-derived residues in the/5 
sheet region,  and DRw53-derived residues in the putative 
c~-helical portion of the antigen-binding domain, as well as 
in the/32 domain. The mutant, DR 531.59, had the/3 sheet 
from DRw53 and DR1 residues in the remainder of the mol- 
ecule. This latter  molecule was able to bind SEA and SEE, 
whereas DR 153.59 was not (Fig. 1 C). This suggests that 
the residues responsible for the high-affinity binding of these 
two toxins lie in the region of residues 59-94. This was tested 
directly with a final pair ofhomologue mutants created from 
the first two. DR 1.53.1 had DRl-derived residues in the 
/3 sheet and/32 domains, and DRw53-derived residues in the 
or-helical portion of the/3 chain. DR 53.1.53 had the cx-helical 
portion (amino acids 59-94) derived from DR1, and the re- 
mainder of the/3 chain  was derived from DRw53. As ex- 
pected,  only DR 53.1.53 bound SEA and SEE (Fig.  1 D). 
In each pair of homologous mutants,  high-affinity binding 
of SEA/SEE was determined by sequences in the oe helix of 
the DR1 ~ chain, although other/3 chain sequences appeared 
to affect the quantitative  level of this binding.  For example, 
in Fig. 1, compare A and B to C and D. The highest binding 
was seen when the entire/31 domain of DR1 was present 
(DR1 wild-type and the 153.94 mutant).  When the DR1 
ot helix was present in conjunction with the Dl{w53/3 sheet 
(mutants  531.59 and  53.1.53),  there was reduced  binding. 
Either there is participation  of sequences outside the ot helix 
in direct SEA/SEE contact, or an influence on the conforma- 
tion of the ot helix by amino acid residues that are distant 
in the/3 chain primary sequence but nearby in the tertiary 
structure. 
Residue 81 Is Critical  for SEA and SEE Binding.  A com- 
parison of the DR1 and DRw53/3 chain amino acid sequences 
from residues 59-96 is shown in Fig. 2. There are five differ- 
ences between these two alleles in this region.  Positions 70, 
74, 86, and 96 are all highly variable among the known/3 
chain  sequences and  are presumably responsible  for differ- 
ences in  antigen  presentation  among DR alleles. Previous 
reports have documented SEA binding by DR alleles differing 
from DR1 at one or more of these positions (10, 24). In con- 
trast, the occurrence of tyrosine at position 81 in the DRw53 
/3 chain is unique to this allele. All other DR 3  chains, as 
well as the/3 chains  of HLA-DQ, HLA-DP, I-E,  and  I-A 
(except A~ [33]), have histidine at this position.  The DRw14 
(Dwg)/3 chain (DRBI*1401)  is thought to be the result of 
a gene conversion event between the DRB1 and DRB4 loci 
(34). The region coding for the/3 sheet portion of the/31 
domain has nucleotide sequence similarity  to several DRB1 
alleles including DRw11, w12, w13, w17, and w18.  How- 
ever, the sequence in the oe helix appears to be derived from 
the DRw53 allele except that there is a histidine at position 
81. The 32 domain of this allele appears to be derived from 
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Figure 2.  Comparison of amino add s%u~ces of [-~A-DRt, -OR.w53, 
and DRw14 (Dw9). The protein sequence (single-letter  amino acid code) 
from residue 59-96 is shown. Boxed residues are the allelic differences be- 
tween DR1 and DRw53 in this  region. 
DR~  as well. An L cell transfectant expressing the DRw14 
(Dw9) class II molecule was made and found to bind SEA 
and SEE (Fig. 3). Thus histidine 81 was the most likely res- 
idue controlling  SEA and SEE binding. 
To test the role that residue 81 may play in the binding 
of SEA and SEE to HLA-DP,, a pair of point mutant/~ chains 
were synthesized. The first was a DP,1 B chain with tyrosine 
at position 81; the second was a DRw53 B chain with histi- 
dine at position 81. L cells expressing these mutant DR B 
chains in association with the wild-type DR o~ chain were 
tested for toxin binding (Fig. 3). The mutant,  DR1-81HY 
lost most, but not all, of the SEA and SEE binding seen with 
the wild-type DR1 molecule.  More significantly,  the mu- 
tant DRw53-81YH bound both toxins at levels comparable 
with other DR alleles. Therefore, the introduction of histi- 
dine at position 81 of the DR B chain restored SEA and SEE 
binding to a DR B chain which otherwise would be unable 
to bind  these toxins. 
Superantigen-induced  T  Cell Proliferation.  The  ability  of 
point-mutated DR molecules to stimulate T cells in the pres- 
ence of SEA or SEE was tested (Fig. 4). As shown previously 
(24), DILw53 was much less e~cient than DR1 in the SEA- 
induced  stimulation  of purified  T  cells.  Both  the  mutant 
DRw53 with histidine at position 81, and the mutant DR1 
with tyrosine at position 81, were intermediate in the ability 
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Figure 4.  Enterotoxin-induced  T cell proliferation.  Highly purified T 
cells were incubated with untransfected  L cells or L cells expressing wild- 
type or mutant DR. molecules, and the indicated concentrations  of SEA 
or SEE. The induced T cell proliferation was measured by [3H]thymidine 
incorporation.  Each point represents the mean of triplicate determinations. 
(.4) Proliferation in response to SEA. (B) Proliferation in response to SEE. 
(ll) DAP-3 (untransfected  L cells); (O), L cells expressing DR.1; (A), 
L cells expressing DR.w53; (O), L cells expressing the DR1-81HY point 
mutant;  (A), L cells expressing  the DR53-81YH point mutant. 
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Figure 3.  Binding of staphylococcal toxins to DRw14 and to DR1 and 
DR.w53 point mutants.  L cells stably expressing the indicated class II mol- 
ecules were tested for toxin binding as in Materials  and Methods.  Solid 
bar, DR.w14; hatched bar, DR.1-81HY; shaded bar, DR53-81YH. 
to stimulate T  cells in the presence of SEA. The similarity 
in the ability of these two mutants to cause T cell prolifera- 
tion is unlike their wide disparity in the ability to bind toxins 
at saturation (Fig. 3). This is similar to previous data showing 
that  HLA-DP can cause marked T  cell proliferation in the 
presence of TSST although direct binding cannot be demon- 
strated (11). T cell proliferation is therefore a more sensitive 
assay for the low level of toxin-class II interaction that results 
from the residual binding  seen with  DR1-81HY. 
It is not clear why there is submaximal T cell stimulation 
by the mutant DRw53-81YH, despite a high relative toxin 
binding (Fig.  3). It is known that aUelic differences in class 
II that  do not affect  toxin binding result in variation in T 
cell stimulation by superantigens (24). It is possible that struc- 
tural features distinct from those responsible for SEA/SEE 
binding determine the ability of this allele to interact with 
T  cell receptors when bound to  these toxins. 
The DR1-81HY Mutation Does Not Prevent T Cell Recogni- 
tion.  It is possible that the mutation ofhistidine to tyrosine 
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Figure  5.  Cytotoxic T  cell assays. Three  DR1- 
restricted T cell lines specific for the hemagglutinin 
peptide H3(307-318)  were tested for their ability to 
lyse a B cell line (B-LCL, a-c), a DRl-expressing L 
cell (DR1, d-J~, and a DR1-81HY-expressing  L cell 
(DR1-81HY, g-0. Specific lysis was measured at the 
indicated E/T ratios. Target cells were either untreated 
(O), incubated with peptide (0), incubated with SEA 
(m), or SEE (A). 
in DR1 abrogated the ability to bind SEA and SEE, not by 
selective disruption of the toxin binding site, but by causing 
more extensive changes in the conformation of the class II 
molecule. The L ceils expressing the class II point mutants 
DRI-18HY  and DRw53-81YH  were compared with cells 
expressing wild-type DILl or DRw53 for their ability to bind 
the mAbs SG465, L243, and SG250. The first two antibodies 
react with determinants that require both the ot and ~ chains 
of human class II (35) or HLA-DR, respectively.  SG520 is 
specific for a monomorphic determinant on the/~ chain (36). 
There was no difference in the relative levels of staining among 
these three antibodies for any of the cell lines tested (data 
not shown), suggesting that the conformation of the mu- 
tants was not grossly altered. 
One of the most critical ways to evaluate the functional 
conformation of an MHC molecule is to test its ability to 
present peptide antigen. This requires that the ability to bind 
the particular peptide be preserved and that the peptide-MHC 
combination result in a recognizable TCR ligand. A panel 
of DKi-restricted human T cell lines specific for peptides de- 
420  Superantigen Binding to HLA-DR Table  1.  Summary of Staphylococcal Enterotoxin-dependent 
Cytotoxicity  and Reactivity  to DRI-81HY  in a Panel of Human 
T  Cell Lines 
Reactivity 
DP,1-81HY 
Line  Specificity  SEA*  SEE*  +  peptide* 
B3.10  M1  18-29  0.08  (0.011)  0.47 (0.042)  + 
F3.1  M1  18-29  ND  ND  + 
H3.12  M1  18-29  0.75  (0.233)  0.98  (0.007)  + 
C3.5  M1  18-29  0.42  (0.255)  0.83  (0.247)  - 
C1.6  H3 307-318  0.89  (0.167)  0.44 (0.067)  - 
E1.9  H3 307-318  0.92  (0.042)  0.88  (0.057)  + 
C3.4  H3 307-318  ND  ND  + 
D1.10  H3 307-318  0.0 (0.085)  0.05  (0.156)  + 
*  Reactivity to toxin expressed as lysis of targets incubated with toxin 
divided by the lysis of targets incubated with 10/~g/ml antigenic pep- 
tide (SD). 
* Lysis of DR1-81HY transfectants incubated with antigenic peptide was 
scored positive when it was >40% of the lysis obtained with the wild- 
type DR1 transfectant  in the same conditions. 
rived from the matrix  (M1) and hemagglutinin  (H3) pro- 
teins of influenza were established.  Of the 10 lines, eight were 
able to recognize peptide presented by transfected mouse L 
cells. Transfected L cells are in general recognized much less 
efficiently than human B cell lines by human T cells. Those 
eight lines were tested for their ability to recognize peptide 
presented by L cells expressing the DR1-81HY molecules. 
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Figure 6.  Location of residue 81 on the class II structural model. The 
proposed three-dimensional structure  of the antigen-binding  domain of 
a class II molecule is shown (adapted from reference 32; reprinted from 
Nature (Lond.) 1988, 332: 845-850, by copyright permission of MacmiUan 
Magazines, Ltd.). The position of the conserved pentapeptide, C-R-H-N-Y 
is indicated,  as is the disulfide bond linking cysteine 79 in the cx hdix 
with cysteine 15 in the B strand below. 
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Despite the fact that these transfectants expressed one-third 
to one-half the level of DR molecules present on the DR1- 
transfected L cells  (not  shown),  most T  cells were able to 
recognize peptide presented by the DR1-81HY molecule (Fig. 
5 and Table 1).  Six of the eight T  cell lines  (three each of 
the anti-M1 and anti-H3) were able to lyse the transfectant 
expressing DR1-81HY after incubation with the relevant pep- 
tide. Thus, the failure of this class II molecule to bind SEA 
and SEE is not due to a significant conformational change 
in the/31 domain. However, the finding that two of the lines 
did not respond to DR1-81HY when pulsed with peptide 
suggests that the particular amino acid at residue 81 can dic- 
tate recognition by some T  cell receptors. 
The binding of SEA and SEE to the region of the 3 chain 
surrounding position 81 of DR1 may prevent an interaction 
with those T  cell receptors that  are  sensitive to changes in 
this portion of the class II molecule. To study this, the M1- 
and H3-specific T  cell lines were tested for their ability to 
become activated by SEA, and SEE bound to DR1. The 45.1 
B cells were incubated with the toxins, labeled with chromium- 
51, washed, and then used as target cells for the T cell lines. 
Four of the six lines evaluated responded by lysing the target 
cells in the absence of antigenic peptide (e.g., Fig. 5, a and 
c). This included the two lines that required histidine at po- 
sition 81 for recognition of peptide in the context of DR1. 
One of the lines, D1.10, was not stimulated at all by the toxins 
(Fig.  5 b). This clone was able to recognize the H3 peptide 
regardless of the presence of histidine at position 81. The final 
T  cell clone, B3.10,  was stimulated by SEE but not SEA. 
Thus, while the interactions of certain TCK and SEA/SEE 
with class II molecules can be sensitive to changes in the same 
region of the DR ~ chain, these interactions are functionally 
distinct. 
Discussion 
Superantigens such as the SEs are potentially useful reagents 
for the study of MHC/TCR interactions. A first step in un- 
derstanding how superantigens trigger T cells, and whether 
the topology of MHC/TCR is maintained when T cells re- 
spond to superantigens, is to define how these molecules bind 
to class II MHC molecules. The experiments reported here 
document the identification of a specific amino acid residue 
critical for the binding of native SEA and SEE to HLA-DR. 
The ability of class  II molecules to bind these two toxins 
and subsequently stimulate T cells was dependent on the pres- 
ence of histidine at position 81 of the ~ chain.  This residue 
is part of a conserved sequence, C-R-H-N-Y, in the putative 
ol-helical portion of the 31 domain. It is found in all reported 
class  II B chain  sequences of humans  and mice except the 
HLA-DRw53 and I-A  u alleles. The single replacement of the 
tyrosine at position 81 of the DRw53 ~  chain by histidine 
was sufficient to restore normal binding  of SEA and SEE, 
whereas most of the binding to DR1 was lost by the replace- 
ment  of histidine by tyrosine. 
The ability of the natural and mutated dass II molecules 
to stimulate T cells in the presence of SEA and SEE was similar 
qualitatively  to  the  binding  data.  However,  the  mutant DR.w53-81YH was still less potent than DR.1.  Conversely, 
DR1-81HY was still more potent than DRw53. These results 
are consistent with the possibility that polymorphic MHC 
residues contacting the TCR contribute to the T cell response 
in conjunction with the V3/superantigen contacts.  Clonal 
T cells respond differently to the same toxin bound to different 
alleles of HLA-DR (24).  This would be in agreement with 
the view that superantigens strengthen rather than disrupt 
the class II/TCR interaction (6). 
The full extent of the binding site of SEA and SEE cannot 
be predicted from the data presented here. However, these 
experiments argue strongly that necessary contact residues 
are in the conserved sequence at positions 79-83 of the 3 
chain. First, although the single amino acid substitutions de- 
scribed here may cause local changes in secondary structure, 
it would be unusual for them to cause global conformational 
changes affecting a distant binding site.  Second, there was 
no difference in the reactivity of the two point mutants with 
a panel of mAbs to either monomorphic determinants lo- 
cated on the 3  chain alone or combinatorial determinants 
requiring both the ol and the 3  chains.  Lastly,  a majority 
of T  cell lines specific for peptides derived from influenza 
and restricted by DR1 were capable of responding to these 
peptides presented by the mutant DR1-81HY.  The interac- 
tion of T cell receptor with class II and peptide is complex, 
involving five separate polypeptide chains. It is therefore im- 
probable that the mutation that caused a loss of SEA and 
SEE binding activity would also cause significant conforma- 
tional changes in the rest of the class II molecule, particu- 
larly in the antigen-binding groove. 
It is not surprising that SEA and SEE have similar class 
II binding characteristics. They are 82%  similar in amino 
acid sequence and cross-react serologically (37,  38).  There 
are  significant  differences in  their  secondary and  tertiary 
structures predicted by circular dichroism and fluorescence 
quenching (39). The NH2-terminal portion of SEA (residues 
1-45) has been suggested to be responsible for binding to 
class II molecules (25). This region has extensive primary se- 
quence similarity to  SEE.  In  addition,  both  proteins  are 
predicted to contain similar o~ helix and 3  sheet structures 
in this region. Other regions of these two toxins have much 
less similarity in the arrangement of putative helix,  sheet, 
and fl turn structures. The functional consequence of this 
is the ability of certain T  cell receptors to distinguish be- 
tween SEA and SEE (Table  1, clone B3.10). 
The staphylococcal toxins SEB and TSST bind to distinct 
sites on HLA-DR (23). SEA will compete with both of these 
toxins for binding to L cells transfected with DR1 (D. Karp, 
unpublished observations), suggesting that all three toxins 
bind to the same general region of class II, although with 
distinct contact points. The identification of histidine 81 as 
a critical element for SEA and SEE binding forms the starting 
point for further investigations into the nature of other toxin 
binding sites, with the aim of understanding how superan- 
tigens as MHC/TCR  coligands (40)  achieve  their potent 
effects. 
The current model of the three-dimensional structure of 
class II places residues 79-83 of the fl chain on a turn of oe 
helix with residue 81 facing away from the antigen-binding 
groove (Fig.  6) (32).  This is appropriate if this sequence is 
involved in binding staphylococcal toxins. This portion of 
the helix also overlies the NH2-terminal end of the c~ chain, 
allowing a possible  role for both chains in the toxin-class 
II interaction. There are strong theoretical and experimental 
reasons to model class II based on the class I crystal structure. 
However, it is not known how primary sequence differences 
between class I and class II will ultimately be reflected in 
the class II secondary or tertiary structure. For example, the 
region of the oe helix discussed above is predicted to be fl 
turn by both Gamier et al. (41) and Chou-Fasman algorithms 
(42). The probability of a fl turn is much larger in the class 
II fl chain sequence than in the class I c,2 sequence. Obvi- 
ously, there are other constraints on the structure in this re- 
gion (including the disulfide bond between the oL helix and 
the fl strand beneath). A fl turn-like structure in this area 
would be an attractive feature for a protein-protein interac- 
tion such as toxin binding. The residues at positions 79-83 
of the class II fl chain comprise the five amino acids with 
the highest degree of conservation across isotypic, allelic, and 
species boundaries. A potential physiologic role of this struc- 
tural feature in the interaction with other ligands is not known. 
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